U.S. Machinery Stock News

NYSE:FHN
NYSE:FHNBanks

First Horizon’s New CISO Appointment And What It Means For Investors

First Horizon (NYSE:FHN) has appointed Leilani Farol as Senior Vice President and Chief Information Security Officer. Farol will lead the bank's enterprise cybersecurity strategy and data protection efforts. For you as an investor, this move highlights how seriously First Horizon is treating cybersecurity at a time when digital risks are front and center for financial institutions. The company’s shares last closed at $24.56, with a 1 year return of 14.4% and a 5 year return of 78.3%, which...
NYSE:NSP
NYSE:NSPProfessional Services

Insperity Cost Cuts And HRScale Rollout Test Valuation Gap

Insperity (NYSE:NSP) is rolling out major cost-cutting measures, including a reduction in non-sales staff and tighter expense controls, in response to profitability pressure. The company is targeting a $20 million cut in operating expenses while pushing ahead with HRScale, its new mid-market HR platform developed with Workday. HRScale is aimed at thousands of employees across small and mid-sized businesses, signaling a shift in how Insperity serves the mid-market HR segment. For investors...
NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride Growth Plans Test Valuation And Earnings Outlook

Pilgrim's Pride is expanding its Just Bare brand and planning new growth projects as it responds to current industry conditions. The company is preparing investments in a new Georgia facility and increasing capital deployment in Mexico. These moves come while Pilgrim's Pride manages challenges such as commodity price swings and pressure on margins. Pilgrim's Pride, traded as NasdaqGS:PPC, is pushing ahead with brand and capacity expansion while its shares trade around $43.32. Over the past...
NYSE:GWW
NYSE:GWWTrade Distributors

Why W.W. Grainger (GWW) Is Down 5.5% After Mixed 2025 Results, 2026 Guidance And New Lawsuit

W.W. Grainger, Inc. recently reported past fourth-quarter 2025 results showing sales of US$4,425 million and full-year 2025 sales of US$17.94 billion, alongside issuing 2026 net sales guidance of US$18.70 billion to US$19.10 billion while also facing a new California labor class action alleging wage and hour violations. Despite higher sales, the company’s 2025 net income and earnings per share from continuing operations declined, highlighting pressure on profitability as it invests in...
NYSE:AJG
NYSE:AJGInsurance

Can Gallagher (AJG) Defend Its Brokerage Moat As AI Tools Challenge Traditional Intermediaries?

In early February 2026, Gallagher Re appointed Minesh Jani, a reinsurance veteran with over three decades of experience and most recently Managing Director of Howden Insurance Brokers’ DIFC branch, as CEO for its India operations. Around the same time, OpenAI’s launch of insurance-native AI tools sparked sector-wide discussion about how far artificial intelligence could displace traditional insurance brokers’ role in matching clients with coverage. We’ll now examine how investor concerns...
NYSE:PFGC
NYSE:PFGCConsumer Retailing

Assessing Performance Food Group’s Valuation After Profit Miss And Ongoing Integration Headwinds

Quarterly miss, integration costs and deflation in focus Performance Food Group (PFGC) recently reported quarterly results where profit fell short of market expectations as Cheney Brothers integration costs and deflation in categories like cheese and poultry pressured margins, even as revenue continued to grow. Management reaffirmed revenue guidance for the upcoming quarter and maintained a positive longer term growth outlook. Analysts noted that higher operating expenses and acquisition...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance

Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda. These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market. Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...
NasdaqGS:PAA
NasdaqGS:PAAOil and Gas

Is Plains All American Pipeline (PAA) Pricing Reflective Of Its Strong Multi‑Year Share Recovery?

If you are looking at Plains All American Pipeline and wondering whether the current price reflects its true worth, this article will help you frame that value question clearly. The stock last closed at US$20.15, with returns of 3.9% over 7 days, 5.7% over 30 days, 10.7% year to date, 11.0% over 1 year and a very large gain over 5 years that points to a big shift in how the market has treated the company over time. Recent coverage around Plains All American Pipeline has focused on its role...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Roku (ROKU) Profit Swing To US$0.54 Q4 EPS Tests Long Term Bearish Narratives

Roku’s FY 2025 results reset the profit story Roku (ROKU) closed out FY 2025 with Q4 revenue of about US$1.4 billion and basic EPS of US$0.54, capping a year in which trailing twelve month revenue reached roughly US$4.7 billion and EPS landed at US$0.60. The company has seen quarterly revenue move from US$1.20 billion in Q4 2024 to US$1.39 billion in Q4 2025, while basic EPS shifted from a loss of US$0.24 to a profit of US$0.54. This gives investors a clearer view of how margins are now...
NasdaqGS:CINF
NasdaqGS:CINFInsurance

Cincinnati Financial (CINF) Is Down 5.7% After Resilient Q4 Earnings And Record Cat Losses - What's Changed

Cincinnati Financial Corporation recently reported fourth-quarter 2025 results, with revenue rising to US$3,091 million and net income to US$676 million, while basic earnings per share from continuing operations increased to US$4.34 from US$2.59 a year earlier. Beyond the headline beats, the insurer renewed key reinsurance treaties on improved terms and achieved underwriting profit despite experiencing the largest catastrophe loss in its history, underscoring the resilience of its business...
NYSE:LDOS
NYSE:LDOSProfessional Services

Leidos Deepens Role In Defense AI Security And Long Term IT Programs

Leidos Holdings (NYSE:LDOS) is accelerating migrations of Defense Agencies to DODNet as part of the multi billion dollar Defense Enclave Services program. The company secured a federal contract to deliver integrated AI and Zero Trust security solutions for critical defense networks. Leidos announced new partnerships with RegScale and Trustible to automate cybersecurity compliance, continuous monitoring, and AI risk management for federal agencies. For investors watching defense IT...
NasdaqGS:CVRX
NasdaqGS:CVRXMedical Equipment

CVRx (CVRX) Q3 Loss Near US$12.9 Million Reinforces Profitability Concerns Despite Growth Narratives

Setting the scene on CVRx's latest results CVRx (CVRX) has reported third quarter FY 2025 revenue of US$14.7 million with a basic EPS loss of US$0.49, alongside trailing twelve month revenue of US$56.0 million and a basic EPS loss of US$2.02, giving investors a clear view of a company still in investment mode. The company has seen quarterly revenue move from US$11.8 million in Q2 2024 to US$14.7 million in Q3 2025. Quarterly basic EPS losses have ranged between US$0.43 and US$0.65 over the...
NYSE:NEU
NYSE:NEUChemicals

Has The Recent Share Price Slide Opened An Opportunity In NewMarket (NEU)?

Are you wondering if NewMarket's current share price reflects its real worth, or if the recent moves have opened up a mispricing you could potentially take advantage of? The stock last closed at US$592.80, after an 18.1% decline over the past week and a 16.4% decline over the past month. This comes even though the 1 year, 3 year and 5 year returns sit at 11.1%, 82.1% and 67.3% respectively. Recent attention on NewMarket has focused on its role in the materials sector and how investors are...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian Automotive (RIVN) Earnings Highlight Persistent US$811 Million Q4 Loss Challenging Bullish Narratives

Rivian Automotive (RIVN) just closed out FY 2025 with fourth quarter revenue of US$1.3 billion, a basic EPS loss of US$0.66, and net income loss of US$811 million, setting the tone for how investors will read the full year. Over the past six quarters, revenue has moved between US$874 million in Q3 2024 and US$1.7 billion in Q4 2024, while quarterly basic EPS has ranged from a loss of US$0.48 in Q1 2025 to a loss of US$1.08 in Q3 2024. This highlights a business that is scaling the top line...
NasdaqGS:MLKN
NasdaqGS:MLKNCommercial Services

Is It Too Late To Consider MillerKnoll (MLKN) After Recent Share Price Rebound

If you are wondering whether MillerKnoll at around US$21.78 still offers value or if the easy gains are gone, this article will explain what the current price reflects in more detail. The stock has shown a mixed pattern, with a 13.2% return over the last 30 days and 19.3% year to date, but a 3.4% decline over the past week and a 32.0% decline over five years that some investors may still have in mind. Recent coverage has focused on how MillerKnoll fits into the commercial services and office...
NYSE:FBIN
NYSE:FBINBuilding

Margin Compression To 6.7% Tests Bullish Smart Home Narrative At Fortune Brands Innovations (FBIN)

How Fortune Brands Innovations' FY 2025 Numbers Stack Up Against the Story Fortune Brands Innovations (FBIN) just closed out FY 2025 with Q4 revenue of US$1,077.5 million and basic EPS of US$0.63, alongside net income of US$76.4 million, putting fresh numbers on the table for investors watching the story play out. The company has seen quarterly revenue range from US$1,033.1 million to US$1,203.3 million over the year, while basic EPS moved between US$0.42 and US$0.83. This gives a clearer...
NYSE:FRT
NYSE:FRTRetail REITs

Federal Realty (FRT) Reports Q4 FFO Loss Challenging Bullish Narratives On Earnings Quality

Federal Realty Investment Trust posts mixed FY 2025 finish as one off item weighs on FFO Federal Realty Investment Trust (FRT) has wrapped up FY 2025 with Q4 revenue of US$334.4 million, Basic EPS of US$1.50 and Funds From Operations of a US$465.1 million loss, while trailing twelve month revenue came in at about US$1.3 billion and Basic EPS at US$4.69. Over recent periods, revenue has moved from US$312.8 million in Q4 2024 to US$334.4 million in Q4 2025, while Basic EPS has shifted from...
NYSE:CTRE
NYSE:CTREHealth Care REITs

CareTrust REIT (CTRE) Earnings Growth Challenges Cautious Narratives On Dilution And Dividend Coverage

CareTrust REIT (CTRE) FY 2025 earnings snapshot CareTrust REIT (CTRE) has just wrapped up FY 2025 with fourth quarter revenue of US$134.9 million and basic EPS of US$0.50, rounding out a trailing twelve month revenue line of US$476.4 million and EPS of US$1.57. Over the past few reported periods, revenue has moved from US$86.9 million in Q4 2024 to US$134.9 million in Q4 2025, while quarterly basic EPS shifted from US$0.29 to US$0.50. The trailing net profit margin was reported at 67.3%,...
NYSE:LNC
NYSE:LNCInsurance

Lincoln National Q3 Margin Recovery Reinforces Bullish Valuation Narratives

Lincoln National’s FY 2025 Earnings Snapshot Lincoln National (LNC) has just put fresh numbers on the table, with Q3 FY 2025 revenue of US$4.6 billion and basic EPS of US$2.15 setting the tone for its latest update. The company has seen quarterly revenue move from US$4.2 billion in Q3 FY 2024 to US$4.6 billion in Q3 FY 2025, while basic EPS has swung from a loss of US$3.29 to a profit of US$2.15 over the same period. This highlights how reported earnings have shifted across the past year...
NYSE:TOST
NYSE:TOSTDiversified Financial

Toast (TOST) Margin Breakthrough Reinforces Bullish Profitability Narratives

Toast FY 2025 earnings snapshot Toast (TOST) reported first half FY 2025 revenue of US$2.9b with basic EPS of US$0.24, setting the tone for a year where profitability is firmly in focus. The company has seen revenue move from US$2.3b in the first half of 2024 to US$2.6b in the second half and then to US$2.9b in the first half of 2025. Over the same periods, basic EPS shifted from a loss of US$0.13 in early 2024 to US$0.16 and then US$0.24. With trailing net margins now higher than a year ago...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

Has The Pullback In Science Applications International (SAIC) Opened A Valuation Opportunity?

If you are wondering whether Science Applications International is starting to look interesting at current levels, this article will walk through what that price actually implies for its underlying value. The stock closed at US$86.61, with returns of an 11.9% decline over the past 7 days, a 19.9% decline over 30 days, a 14.4% decline year to date and a 13.0% decline over 1 year, as well as a roughly flat 0.1% gain over 5 years, which may have shifted how investors see its risk and potential...
NasdaqCM:IMUX
NasdaqCM:IMUXBiotechs

A Look At Immunic (IMUX) Valuation After CEO Transition MS Data And US$200m Financing

Immunic (IMUX) has been in focus after a busy stretch, with board and leadership changes, fresh clinical data in multiple sclerosis, and a large private placement that brought in new and existing institutional investors. See our latest analysis for Immunic. The recent CEO transition plan, fresh MS data and the US$200.0m private placement appear to have coincided with sharp short term momentum, with a 7 day share price return of 47.18% and year to date share price return of 56.52%. This is set...
NasdaqGS:CLBK
NasdaqGS:CLBKBanks

Columbia Financial Northfield Merger Puts Focus On Growth And Execution Risks

Columbia Financial, NasdaqGS:CLBK, has announced an agreement to acquire Northfield in a significant merger deal. The transaction is expected to combine two established regional banking franchises and materially change Columbia Financial's business profile. Investors are watching the deal for its potential impact on Columbia Financial's operations, balance sheet mix, and market reach. For shareholders, the news arrives with Columbia Financial shares at $18.41 and a mixed return profile. The...
NasdaqGS:PACB
NasdaqGS:PACBLife Sciences

Pacific Biosciences Of California (PACB) Q4 Losses Highlight Ongoing Profitability Concerns Despite Revenue Base

Pacific Biosciences of California (PACB) just wrapped up FY 2025 with Q4 revenue of about US$44.6 million and a basic EPS loss of US$0.13, alongside a full year trailing revenue base of roughly US$160.0 million and a trailing basic EPS loss of US$1.82. Over recent quarters, the company has seen revenue move from US$39.2 million in Q4 2024 to US$44.6 million in Q4 2025. Quarterly basic EPS has shifted from a small profit of US$0.01 in Q4 2024 to losses between US$0.13 and US$1.44 across FY...